Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseBlastic Plasmocytoid Dendritic Cell NeoplasiaSubgroupICD10MeSHSequenceChemotherapyChemo-substanceTagraxofuspChemo-substanceTagraxofuspChemo-substanceTagraxofuspChemo-substanceTagraxofuspNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDimetindenNaCl 0.9%ParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineDimetindenNaCl 0.9%ParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineDimetindenNaCl 0.9%ParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineDimetindenNaCl 0.9%ParacetamolPrednisoloneNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCapillary Leak SyndromeEdemaEmetogenicityHeadacheHepatotoxicityHyperglycemiaHypertensionHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypotensionNeutropeniaPyrexiaThrombocytopenia below 50 000/µl only studiesPublicationAuthorPemmaraju NDiseaseBlastische plasmazytoide dendritische Zellneoplasie, ECOG 0-2OriginUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 1 protocol foundProtocols under revision.Tagraxofusp 12, Blastic plasmocytoid dendritic cell neoplasia (PID1824 V1.0)
